  | Pierre, N., Vieujean, S., Peyrin-Biroulet, L., Meuwis, M.-A., & Louis, E. (2023). Defining biological remission in Crohn's disease: interest, challenges and future directions. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjad086  Peer Reviewed verified by ORBi |
 | Pierre, N., Huynh-Thu, V. A., Marichal, T., Allez, M., Bouhnik, Y., Laharie, D., Bourreille, A., Colombel, J.-F., Meuwis, M.-A., Louis, E., & GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif). (2022). Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity. Gut, 2022-327321. doi:10.1136/gutjnl-2022-327321 Peer Reviewed verified by ORBi |
 | Pierre, N., Salée, C., Vieujean, S., Bequet, E., Merli, A.-M., Siegmund, B., Meuwis, M.-A., & Louis, E. (2021). Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Alimentary Pharmacology and Therapeutics, 54 (6), 779-791. doi:10.1111/apt.16536 Peer reviewed |
 | Pierre, N., Baiwir, D., Huynh-Thu, V. A., Mazzucchelli, G., Smargiasso, N., De Pauw, E., Bouhnik, Y., Laharie, D., Colombel, J.-F., Meuwis, M.-A., & Louis, E. (2021). Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. Gut. doi:10.1136/gutjnl-2020-322100 Peer Reviewed verified by ORBi |
 | Pierre, N., Salee, C., MASSOT, C., BLETARD, N., Mazzucchelli, G., Smargiasso, N., Morsa, D., Baiwir, D., De Pauw, E., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Delvenne, P., Meuwis, M.-A., & Louis, E. (2019). Proteomics highlights common and distinct pathophysiological processes associated with ileal and colonic ulcers in Crohn's disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjz130 Peer Reviewed verified by ORBi |
